Ovarian Response to Intraovarian Platelet-rich Plasma (PRP) Administration: Hypotheses and Potential Mechanisms of Action

Overview

Journal J Assist Reprod Genet

Publisher Springer

Specialties Genetics
Reproductive Medicine

Date 2022 Feb 17

PMID 35175511

Authors

Serin Seckin

Hadi Ramadan

Marco Mouanness

Michelle Kohansieh

Zaher Merhi

Affiliations

Soon will be listed here.

Abstract

Purpose: Platelet-rich plasma (PRP) therapy has been used as an adjunct to fertility treatments in women with very low ovarian reserve and premature ovarian insufficiency. Recent literature in both humans and animals suggest that intraovarian PRP administration in the setting of poor ovarian reserve may help ovarian function and increase the chances of pregnancy.

Methods: A comprehensive literature search through PubMed, MEDLINE databases, and recent abstracts published at relevant society meetings was performed and resulted in 25 articles and 2 abstracts published that studied effect of PRP on the ovaries for the purpose of reproduction.

Results: This review article presents all the data published to date pertaining to intraovarian PRP injection and pregnancy, both naturally and after in vitro fertilization. It also presents the most recent data on the use of ovarian PRP in in vitro and animal model studies highlighting the possible mechanisms by which PRP could impact ovarian function.

Conclusions: Even though recent commentaries questioned the use of PRP as an "add-on" therapy in fertility treatment because it has not been thoroughly studied, the recent basic science studies presented here could increase awareness for considering more serious research into the efficacy of PRP as an adjunct for women with poor ovarian reserve, premature ovarian insufficiency, and even early menopause who are trying to conceive using their own oocytes. Given its low-risk profile, the hypothetical benefit of PRP treatment needs to be studied with larger randomized controlled trials.

Citing Articles

Platelet-Rich Plasma and Electrochemical Biosensors: A Novel Approach to Ovarian Function Evaluation and Diagnostics.

Ivaskiene T, Kaspute G, Bareikiene E, Prentice U Int J Mol Sci. 2025; 26(5).

PMID: 40076937 PMC: 11899975. DOI: 10.3390/ijms26052317.

Editorial: The role of metabolomics in ART: from diagnosis to treatment.

Simopoulou M, Grigoriadis S, Maziotis E, Cretoiu D, Mastorakos G, Sturmey R Front Endocrinol (Lausanne). 2025; 16:1558561.

PMID: 39974823 PMC: 11835697. DOI: 10.3389/fendo.2025.1558561.

Novel Molecular Mechanisms Underlying the Ameliorative Effect of Platelet-Rich Plasma against Electron Radiation-Induced Premature Ovarian Failure.

Demyashkin G, Vadyukhin M, Murtazalieva Z, Pugacheva E, Schekin V, Bimurzaeva M Int J Mol Sci. 2024; 25(18).

PMID: 39337598 PMC: 11432445. DOI: 10.3390/ijms251810115.

Intraovarian Platelet-Rich Plasma Administration for Anovulatory Infertility: Preliminary Findings of a Prospective Cohort Study.

Potiris A, Stavros S, Voros C, Christopoulos P, Pouliakis A, Savvidis M J Clin Med. 2024; 13(17).

PMID: 39274502 PMC: 11396770. DOI: 10.3390/jcm13175292.

Rejuvenation of aged oocyte through exposure to young follicular microenvironment.

Wang H, Huang Z, Shen X, Lee Y, Song X, Shu C Nat Aging. 2024; 4(9):1194-1210.

PMID: 39251866 DOI: 10.1038/s43587-024-00697-x.

References

Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T . A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients. Gynecol Obstet Invest. 2018; 84(1):99-106. DOI: 10.1159/000491697. View

Stojkovska S, Dimitrov G, Stamenkovska N, Hadzi-Lega M, Petanovski Z . Live Birth Rates in Poor Responders' Group after Previous Treatment with Autologous Platelet-Rich Plasma and Low Dose Ovarian Stimulation Compared with Poor Responders Used Only Low Dose Ovarian Stimulation Before in Vitro Fertilization. Open Access Maced J Med Sci. 2020; 7(19):3184-3188. PMC: 6953937. DOI: 10.3889/oamjms.2019.825. View

Pavlovic V, Ciric M, Jovanovic V, Stojanovic P . Platelet Rich Plasma: a short overview of certain bioactive components. Open Med (Wars). 2017; 11(1):242-247. PMC: 5329835. DOI: 10.1515/med-2016-0048. View

Hsu C, Hsu L, Hsu I, Chiu Y, Dorjee S . Live Birth in Woman With Premature Ovarian Insufficiency Receiving Ovarian Administration of Platelet-Rich Plasma (PRP) in Combination With Gonadotropin: A Case Report. Front Endocrinol (Lausanne). 2020; 11:50. PMC: 7043014. DOI: 10.3389/fendo.2020.00050. View

Ahmadian S, Sheshpari S, Pazhang M, Miranda Bedate A, Beheshti R, Mesgari Abbasi M . Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation. Reprod Biol Endocrinol. 2020; 18(1):78. PMC: 7405361. DOI: 10.1186/s12958-020-00638-4. View

Sfakianoudis K, Simopoulou M, Grigoriadis S, Pantou A, Tsioulou P, Maziotis E . Reactivating Ovarian Function through Autologous Platelet-Rich Plasma Intraovarian Infusion: Pilot Data on Premature Ovarian Insufficiency, Perimenopausal, Menopausal, and Poor Responder Women. J Clin Med. 2020; 9(6). PMC: 7355907. DOI: 10.3390/jcm9061809. View

Farimani M, Heshmati S, Poorolajal J, Bahmanzadeh M . A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Mol Biol Rep. 2019; 46(2):1611-1616. DOI: 10.1007/s11033-019-04609-w. View

Sfakianoudis K, Rapani A, Grigoriadis S, Retsina D, Maziotis E, Tsioulou P . Novel Approaches in Addressing Ovarian Insufficiency in 2019: Are We There Yet?. Cell Transplant. 2020; 29:963689720926154. PMC: 7563844. DOI: 10.1177/0963689720926154. View

Laver L, Marom N, Dnyanesh L, Mei-Dan O, Espregueira-Mendes J, Gobbi A . PRP for Degenerative Cartilage Disease: A Systematic Review of Clinical Studies. Cartilage. 2017; 8(4):341-364. PMC: 5613892. DOI: 10.1177/1947603516670709. View

10.

Cakiroglu Y, Saltik A, Yuceturk A, Karaosmanoglu O, Yildirim Kopuk S, Scott R . Effects of intraovarian injection of autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency. Aging (Albany NY). 2020; 12(11):10211-10222. PMC: 7346073. DOI: 10.18632/aging.103403. View

11.

Vural B, Duruksu G, Vural F, Gorguc M, Karaoz E . Effects of VEGF Mesenchymal Stem Cells and Platelet-Rich Plasma on Inbred Rat Ovarian Functions in Cyclophosphamide-Induced Premature Ovarian Insufficiency Model. Stem Cell Rev Rep. 2019; 15(4):558-573. DOI: 10.1007/s12015-019-09892-5. View

12.

Middleton K, Barro V, Muller B, Terada S, Fu F . Evaluation of the effects of platelet-rich plasma (PRP) therapy involved in the healing of sports-related soft tissue injuries. Iowa Orthop J. 2013; 32:150-63. PMC: 3565396. View

13.

Dhurat R, Sukesh M . Principles and Methods of Preparation of Platelet-Rich Plasma: A Review and Author's Perspective. J Cutan Aesthet Surg. 2015; 7(4):189-97. PMC: 4338460. DOI: 10.4103/0974-2077.150734. View

14.

Badsha H, Harifi G, Murrell W . Platelet Rich Plasma for Treatment of Rheumatoid Arthritis: Case Series and Review of Literature. Case Rep Rheumatol. 2020; 2020:8761485. PMC: 7021456. DOI: 10.1155/2020/8761485. View

15.

Petryk N, Petryk M . Ovarian Rejuvenation Through Platelet-Rich Autologous Plasma (PRP)-a Chance to Have a Baby Without Donor Eggs, Improving the Life Quality of Women Suffering from Early Menopause Without Synthetic Hormonal Treatment. Reprod Sci. 2020; 27(11):1975-1982. DOI: 10.1007/s43032-020-00266-8. View

16.

Ozcan P, Takmaz T, Tok O, Islek S, Yigit E, Ficicioglu C . The protective effect of platelet-rich plasma administrated on ovarian function in female rats with Cy-induced ovarian damage. J Assist Reprod Genet. 2020; 37(4):865-873. PMC: 7183018. DOI: 10.1007/s10815-020-01689-7. View

17.

Johnson J, Canning J, Kaneko T, Pru J, Tilly J . Germline stem cells and follicular renewal in the postnatal mammalian ovary. Nature. 2004; 428(6979):145-50. DOI: 10.1038/nature02316. View

18.

Urman B, Boza A, Balaban B . Platelet-rich plasma another add-on treatment getting out of hand? How can clinicians preserve the best interest of their patients?. Hum Reprod. 2019; 34(11):2099-2103. DOI: 10.1093/humrep/dez190. View

19.

Scott Sills E, Rickers N, Wood S . Intraovarian insertion of autologous platelet growth factors as cell-free concentrate: Fertility recovery and first unassisted conception with term delivery at age over 40. Int J Reprod Biomed. 2021; 18(12):1081-1086. PMC: 7778756. DOI: 10.18502/ijrm.v18i12.8030. View

20.

Melo P, Navarro C, Jones C, Coward K, Coleman L . The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study. J Assist Reprod Genet. 2020; 37(4):855-863. PMC: 7183031. DOI: 10.1007/s10815-020-01710-z. View